{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:49:19Z","timestamp":1781196559584,"version":"3.54.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40265-025-02199-5","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T22:15:02Z","timestamp":1750630502000},"page":"1067-1072","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Recaticimab: First Approval"],"prefix":"10.1007","volume":"85","author":[{"given":"Yvette N.","family":"Lamb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"2199_CR1","unstructured":"National Medical Products Administration. Recaticimab: NMPA Approval No. S20250002. 2025."},{"key":"2199_CR2","unstructured":"Hengrui. The world's first ultra-long-acting PCSK9 monoclonal antibody! Hengrui's innovative lipid-lowering drug Relcarcimab was approved for marketing [Google translation] [media release]. 13 Jan 2025. https:\/\/www.hengrui.com\/."},{"key":"2199_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40265-024-01995-9","volume":"84","author":"WAM Schonck","year":"2024","unstructured":"Schonck WAM, Stroes ESG, Hovingh GK, et al. Long-term efficacy and tolerability of PCSK9 targeted therapy: a review of the literature. Drugs. 2024;84:165\u201378.","journal-title":"Drugs"},{"key":"2199_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100701","volume":"19","author":"M Safarova","year":"2024","unstructured":"Safarova M, Bimal T, Soffer DE, et al. Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond. Am J Prevent Cardiol. 2024;19: 100701.","journal-title":"Am J Prevent Cardiol."},{"key":"2199_CR5","doi-asserted-by":"publisher","unstructured":"Coppinger C, Movahed MR, Azemawah V, et al. A comprehensive review of PCSK9 inhibitors. J Cardiovasc Pharmacol Ther. 2022. https:\/\/doi.org\/10.1177\/10742484221100107","DOI":"10.1177\/10742484221100107"},{"issue":"2","key":"2199_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.atherosclerosis.2013.12.003","volume":"233","author":"SP Zhao","year":"2014","unstructured":"Zhao SP, Yu BL, Peng DQ, et al. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: results of the CHILLAS trial. Atherosclerosis. 2014;233(2):707\u201312.","journal-title":"Atherosclerosis"},{"key":"2199_CR7","doi-asserted-by":"publisher","first-page":"1190934","DOI":"10.3389\/fphar.2023.1190934","volume":"14","author":"JJ Li","year":"2023","unstructured":"Li JJ, Zhao SP, Zhao D, et al. 2023 Chinese guideline for lipid management. Front Pharmacol. 2023;14:1190934.","journal-title":"Front Pharmacol"},{"issue":"7","key":"2199_CR8","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1007\/s12325-024-02877-y","volume":"41","author":"P Savage","year":"2024","unstructured":"Savage P, Cox B, Shahmohammadi M, et al. Advances in Clinical Cardiology 2023: a summary of key clinical trials. Adv Ther. 2024;41(7):2606\u201334.","journal-title":"Adv Ther"},{"key":"2199_CR9","unstructured":"Hengrui. Hengrui Medicine's innovative lipid-lowering drug, anti-PCSK9 monoclonal antibody recaticimab, has been accepted for marketing approval [Google translation] [media release]. 21 Jun 2023. https:\/\/www.hengrui.com\/."},{"key":"2199_CR10","unstructured":"Hengrui. Recaticimab for injection: Chinese prescribing information. 2025."},{"issue":"13","key":"2199_CR11","first-page":"1","volume":"20","author":"M Xu","year":"2022","unstructured":"Xu M, Zhu X, Wu J, et al. PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b\/2 study. BMC Med. 2022;20(13):1\u201313.","journal-title":"BMC Med"},{"issue":"20","key":"2199_CR12","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/j.jacc.2024.07.035","volume":"84","author":"M Xu","year":"2024","unstructured":"Xu M, Wang Z, Zhang Y, et al. Recaticimab monotherapy for nonfamilial hypercholesterolemia and mixed hyperlipidemia: the phase 3 REMAIN-1 randomized trial. J Am Coll Cardiol. 2024;84(20):2026\u201336.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2199_CR13","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s11883-023-01164-5","volume":"25","author":"K Gupta","year":"2023","unstructured":"Gupta K, Hinkamp C, Andrews T, et al. Highlights of cardiovascular disease prevention studies presented at the 2023 European Society of Cardiology Congress. Curr Atheroscler Rep. 2023;25(12):965\u201378.","journal-title":"Curr Atheroscler Rep"},{"issue":"20","key":"2199_CR14","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.jacc.2024.09.012","volume":"84","author":"Y Sun","year":"2024","unstructured":"Sun Y, Lv Q, Guo Y, et al. Recaticimab as add-on therapy to statins for nonfamilial hypercholesterolemia: the randomized, phase 3 REMAIN-2 trial. J Am Coll Cardiol. 2024;84(20):2037\u201347.","journal-title":"J Am Coll Cardiol"},{"issue":"33","key":"2199_CR15","doi-asserted-by":"publisher","first-page":"23514","DOI":"10.1074\/jbc.M604292200","volume":"281","author":"WF Dall'Acqua","year":"2006","unstructured":"Dall\u2019Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2006;281(33):23514\u201324.","journal-title":"J Biol Chem"},{"issue":"13, Suppl 2","key":"2199_CR16","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/S0735-1097(24)03697-0","volume":"83","author":"C Jiyan","year":"2024","unstructured":"Jiyan C, Li L, Gao X, et al. PCSK9 monoclonal antibody recaticimab in adult heterozygous familial hypercholesterolemia (REMAIN-3): a multicenter, randomized, double-blind, placebo-controlled phase 3 study [abstract no. 1068\u201309]. J Am Coll Cardiol. 2024;83(13, Suppl 2):1707.","journal-title":"J Am Coll Cardiol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02199-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02199-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02199-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T21:35:28Z","timestamp":1757194528000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02199-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2199"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02199-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"13 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yvette Lamb is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}